Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.
Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.
Standex International reports a robust start to fiscal 2026, with sales climbing 27.6% and a record order book prompting an upward revision of its annual revenue forecast. The company's strategic pivot towards grid modernization and data center markets, highlighted by the rebranded 'Standex Electronics Grid' unit, fuels confidence in exceeding long-term targets.
Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.
Polish cybersecurity authorities have attributed a wave of disruptive cyberattacks in late December to a hacking group linked to Russia's FSB, marking a potential escalation in tactics against energy and heating infrastructure during a severe winter storm.
Standex International reported resilient Q1 2025 earnings with record gross margins above 40%, while announcing a transformative $462 million acquisition of Amran/Narayan Group, a leader in instrument transformers, aiming to double its exposure to fast-growing electrical infrastructure markets.
Oshkosh Corporation topped revenue expectations in its latest quarter, but profit fell short as tariffs and cost pressures squeezed margins. The specialty vehicle maker's 2026 outlook balances targeted growth in some segments against persistent challenges in construction markets.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.
As earnings season concludes, we analyze the performance of construction and maintenance services stocks. While the sector showed overall strength, WillScot Mobile Mini faced headwinds, contrasting with standout results from peers like Comfort Systems.
As earnings season winds down, the waste management sector reveals a tale of resilience and regulatory reckoning. While Enviri's results disappointed, others like Perma-Fix surprised to the upside, highlighting the industry's complex dance between steady demand and economic sensitivity.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
Driven by falling costs and strong incentives, heavy manufacturing is increasingly turning to on-site solar power. This shift is transforming large factory roofs from passive structures into strategic assets for cutting energy bills and emissions.
Allegro MicroSystems (ALGM) reported strong fourth-quarter results, with revenue surging 29% year-over-year to $229.2 million, surpassing analyst expectations. The chip designer's growth was fueled by record data center sales and robust demand in automotive, particularly for electric vehicles and ADAS.
A.O. Smith's Q4 2025 earnings reveal a tale of two stories: revenue that missed expectations but profits that beat them. The water technology leader is leaning into commercial strength and operational discipline to expand margins, even as it braces for a challenging 2026 marked by input cost inflation and persistent softness in its China business.
